Herrington, William G.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 2,479

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 1,983

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,642

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Coresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 338

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, Pennells, L., Kaptoge, S., Østergaard, H. B., Read, S. H., Carinci, F., Franch-Nadal, J., Petitjean, C., Taylor, O., Hageman, S. H. J., et al. (2023) · European Heart Journal

Diabetes, Cardiovascular Risks, and LipoproteinsHealth Promotion and Cardiovascular Prevention

Cited by 329

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 237

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Body-mass index and risk of advanced chronic kidney disease: prospective analyses from a primary care cohort of 1.4 million adults in England

Herrington, W. G., Smith, M., Bankhead, C., Matsushita, K., Stevens, S., Holt, T., Hobbs, F. D. R., Coresh, J., & Woodward, M. (2017) · PLOS ONE

Chronic Kidney Disease and DiabetesCancer Risks and Factors

Cited by 141

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F. E., Shahinfar, S., Tuttle, K. R., Donner, J.-A., Jha, V., Nangaku, M., et al. (2020) · Kidney International

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 125

Conventional and genetic evidence on the association between adiposity and CKD

Zhu, P., Herrington, W. G., Haynes, R., Emberson, J., Landray, M. J., Sudlow, C. L. M., Woodward, M., Baigent, C., Lewington, S., & Staplin, N. (2021) · Journal of the American Society of Nephrology

Genetic Associations and EpidemiologyChronic Kidney Disease and Diabetes

Cited by 83

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

Staplin, N., Roddick, A. J., Emberson, J., Reith, C., Riding, A., Wonnacott, A., Kuverji, A., Bhandari, S., Baigent, C., Haynes, R., et al. (2021) · eClinicalMedicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 74

General and Abdominal Adiposity and Mortality in Mexico City: A Prospective Study of 150 000 Adults

Gnatiuc, L., Alegre-Díaz, J., Wade, R., Ramirez-Reyes, R., Tapia-Conyer, R., Garcilazo-Ávila, A., Chiquete, E., Gonzáles-Carballo, C., Solano-Sanchez, M., Clarke, R., et al. (2019) · Annals of Internal Medicine

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 43

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection

on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 16